Skip to main content
Home
Zeitschriften
Zeitungen
Podcast
Gesundheitspolitik
Praxis
Allerlei
Jobs
Fachgebiete
Allgemeinmedizin Anästhesiologie & Intensivmedizin Apotheke Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kinder & Jugendheilkunde Neurologie & Psychiatrie Orthopädie & Unfallchirurgie Pflege Urologie Zahnmedizin
Subfächer Innere Medizin
Diabetologie Gastroenterologie Infektiologie Kardiologie Onkologie und Hämatologie Pneumologie Rheumatologie
Fortbildungen
Überblick Fortbildungen DFP-Literaturstudium-Artikel DFP-Webcast Fortbildungen DFP-Podcasts
Erweiterte Suche
Anmelden
nach oben
Wiener Medizinische Wochenschrift
Erschienen in:

01.07.2014 | main topic

Vitiligo: what’s new in the psycho-neuro-endocrine-immune connection and related treatments

verfasst von: Torello Lotti, MD, Matteo Zanardelli, Angelo Massimiliano D’Erme, MD

Erschienen in: Wiener Medizinische Wochenschrift | Ausgabe 13-14/2014

Einloggen, um Zugang zu erhalten

Summary

Vitiligo is an acquired depigmentary skin disorder of unknown origin characterized by well-demarcated, white macules of varying size and distribution. Despite relevant new research and progresses, why melanocytes disappear to induce the characteristic achromic lesions of vitiligo is not fully understood. In spite of recent findings implicating genetic, immune and oxidative stress factors, the exact pathogenesis of vitiligo remains obscure. An innovative concept based on a functional cross-talk between the nervous and immune system is emerging. Neuropeptides released from peripheral nerve endings could synergize with new cytokines to adversely affect melanocyte function and viability. Evidence is increasing regarding the role of neuropeptides in the pathogenesis of vitiligo and a new winning approach to vitiligo therapy based on neuropeptides regulation is at the horizon.
Vorheriger Artikel Autoimmunity versus Autoinflammation - Friend or Foe?
Nächster Artikel Pathways of Tumor development and progression in Drug-induced Nonmelanoma Skin Cancer: a New Hope or the Next Great Confusion?
Literatur
1.
Laddha NC, Dwivedi M, Mansuri MS, Gani AR, Ansarullah M, Ramachandran AV, Dalai S, Begum R. Vitiligo: interplay between oxidative stress and immune system. Experimental Dermatology. 2013;22:245–50.PubMedCrossRef
2.
Lotti T, Hercogova J, editors. Vitiligo: problems and solutions. New York: Marcel Dekker; 2004. S. 323–34.
3.
Taieb A, Alomar A, Böhm M, Dell’anna ML, De Pase A, Eleftheriadou V, Ezzedine K, Gauthier Y, Gawkrodger DJ, Jouary T, Leone G, Moretti S, Nieuweboer-Krobotova L, Olsson MJ, Parsad D, Passeron T, Tanew A, van der Veen W, van Geel N, Whitton M, Wolkerstorfer A, Picardo M. The writing group of the Vitiligo European Task Force (VETF) in cooperation with the European Academy of Dermatology and Venereology (EADV) and the Union Européenne des Médecins Spécialistes (UEMS). Guidelines for the management of vitiligo: the European Dermatology Forum consensus. Br J Dermatol. 2013;168(1):5–19.PubMedCrossRef
4.
5.
Hercogová J, Schwartz RA, Lotti TM. Classification of vitiligo: a challenging endeavor. Dermatol Ther. 2012;25(Suppl 1):10–6.CrossRef
6.
Ezzedine K, Lim HW, Suzuki T, Katayama I, Hamzavi I, Lan CC, Goh BK, Anbar T, Silva de Castro C, Lee AY, Parsad D, van Geel N, Le Poole IC, Oiso N, Benzekri L, Spritz R, Gauthier Y, Hann SK, Picardo M, Taieb A. Vitiligo Global Issue Consensus Conference Panelists. Revised classification/nomenclature of vitiligo and related issues: the Vitiligo Global Issues Consensus Conference. Pigment Cell Melanoma Res. 2012;25(3):E1–13.PubMedCentralPubMedCrossRef
7.
Ongenae K, Van Geel N, Naeyaert JM. Evidence for an autoimmune pathogenesis of vitiligo. Pigment Cell Res. 2003;16(2):90–100.PubMedCrossRef
8.
Linthorst Homan MW, Sprangers MA, de Korte J, Bos JD, van der Veen JP. Characteristics of patients with universal vitiligo and health-related quality of life. Arch Dermatol. 2008;144(8):1062–4.PubMedCrossRef
9.
Hann SK, Lee HJ. Segmental vitiligo: clinical findings in 208 patients. J Am Acad Dermatol. 1996;35(5 Pt 1):671–4.PubMedCrossRef
10.
Le Poole IC, Luiten RM. Autoimmune etiology of generalized vitiligo. Curr Dir Autoimmun. 2008;10:227–43.PubMedCrossRef
11.
Alikhan A, Felsten LM, Daly M, Petronic-Rosic V. Vitiligo: a comprehensive overview Part I. Introduction, epidemiology, quality of life, diagnosis, differential diagnosis, associations, histopathology, etiology, and work-up. J Am Acad Dermatol. 2011;65(3):473–91.PubMedCrossRef
12.
Kemp EH, Waterman EA, Weetman AP. Autoimmune aspects of vitiligo. Autoimmunity. 2001;34:65–77.PubMedCrossRef
13.
Mandelcorn-Monson RL, Shear NH, Yau E, Sambhara S, Barber BH, Spaner D, De Benedette MA. Cytotoxic T lymphocyte reactivity to gp100, MelanA/MART-1, and tyrosinase, in HLA-A2-positive vitiligo patients. J Invest Dermatol. 2003 Sep;121(3):550–6.PubMedCrossRef
14.
Steitz J, Wenzel J, Gaffal E, Tuting T. Initiation and regulation of CD8 + T cells recognizing melanocytic antigens in the epidermis: implications for the pathophysiology of vitiligo. Eur J Cell Biol. 2004;83(11–12):797–803.PubMedCrossRef
15.
Harning R, Cui J, Bystryn JC. Relation between the incidence and level of pigment cell antibodies and disease activity in vitiligo. J Invest Dermatol. 1991;97(6):1078–80.PubMedCrossRef
16.
Farrokhi S, Hojjat-Farsangi M, Noohpisheh MK, Tahmasbi R, Rezaei N. Assessment of the immune system in 55 Iranian patients with vitiligo. J Eur Acad Dermatol Venereol. 2005;19(6):706–11.PubMedCrossRef
17.
Lotti T, D’Erme AM, Hercogova J. The role of neuropeptides in the control of regional immunity. Clin Dermatol. (In press).
18.
Roosterman D, Goerge T, Schneider SW, Bunnett NW, Steinhoff M. Neuronal control of skin function: the skin as a neuroimmunoendocrine organ. Physiol Rev. 2006;86(4):1309–79.PubMedCrossRef
19.
Al’Abadie MSK, Senior HJ, Bleehen SS, Gawkrodger DJ. Neuropeptide and neuronal marker studies in vitiligo. Br J Dermatol. 1994;131:160–5.
20.
Nellhiius G, Acquired unilateral vitiligo and poliosis of the head and subacute encephalitis with partial recovery. Neurology. 1970;20:965–74.CrossRef
21.
Silvan M. The psychological aspects of vitiligo. Cutis. 2004;73(3):163–7.PubMed
22.
Lotti T, Bianchi B, Ghersetich I, Brazzini B, Hercogova J. Can the brain inhibit inflammation generated in the skin? The lesson of gamma-melanocyte-stimulating hormone. Int J Dermatol. 2002;41(6):311–8.PubMedCrossRef
23.
Lotti T, Hautmann G, Panconesi E. Neuropeptides in skin. J Am Acad Dermatol. 1995;33(3):482–96.PubMedCrossRef
24.
Lotti T, Bianchi B, Panconesi E. Neuropeptides and skin disorders. The new frontiers of neuro-endocrine-cutaneous immunology. Int J Dermatol. 1999;38(9):673–5.PubMedCrossRef
25.
Urpe M, Pallanti S, Lotti T. Psychosomatic factors in dermatology. Dermatol Clin. 2005;23(4):601–8.PubMedCrossRef
26.
Urpe M, Buggiani G, Lotti T. Stress and psychoneuroimmunologic factors in dermatology. Dermatol Clin. 2005;23(4):609–17.PubMedCrossRef
27.
Vrijman C, Hosseinpour D, Bakker JG, Wolkerstorfer A, Bos JD, van der Veen JP, Luiten RM. Provoking factors, including chemicals, in Dutch patients with vitiligo. Br J Dermatol. 2013;168(5):1003–11.PubMedCrossRef
28.
Moretti S, Arunachalam M, Colucci R, Pallanti S, Kline JA, Berti S, Lotti F, Lotti T. Autoimmune markers in vitiligo patients appear correlated with obsession and phobia. J Eur Acad Dermatol Venereol. 2012;26(7):861–7.PubMedCrossRef
29.
D’Erme AM, Zanieri F, Campolmi E, Santosuosso U, Betti S, Agnoletti AF, Cossidente A, Lotti T. Therapeutic implications of adding the psychotropic drug escitalopram in the treatment of patients suffering from moderate-severe psoriasis and psychiatric comorbidity: a retrospective study. J Eur Acad Dermatol Venereol. 2012 Sep 11.
30.
31.
Falabella R, Barona MI, Echeverri IC, Alzate A. Substance P may play a part during depigmentation in vitiligo. A pilot study. J Eur Acad Dermatol Venereol. 2003 May;17(3):355–6.PubMedCrossRef
32.
Slominski A, Wortsman J, Tuckey RC, Paus R. Differential expression of HPA axis homolog in the skin. Mol Cell Endocrinol. 2007;265–266:143–9.PubMedCentralPubMedCrossRef
33.
Theoharides TC, Donelan JM, Papadopoulou N, Cao J, Kempuraj D, Conti P. Mast cells as targets of corticotropin-releasing factor and related peptides. Trends Pharmacol Sci. 2004;25(11):563–8.PubMedCrossRef
34.
Slominski A, Wortsman J, Pisarchik A, Zbytec B, Linton EA, Mazurkiewicz JE, Wei ET. Cutaneous expression of corticotrophin releasing hormone (CRH), urocortin and CRH receptors. FASEB J. 2001;15(10):1678–93.PubMedCrossRef
35.
Slominski AT, Tobin DJ, Shibahara S, Wortsman J. Melanin pigmentation in mammalian skin and its hormonal regulation. Physiol Rev. 2004;84:1155–228.PubMedCrossRef
36.
Kingo K, Aunin E, Karelson M, Philips MA, Rätsep R, Silm H, Vasar E, Soomets U, Kõks S. Gene expression analysis of melanocortin system in vitiligo. J Dermatol Sci. 2007;48(2):113–22.PubMedCrossRef
37.
Reimann E, Kingo K, Karelson M, Salum T, Aunin E, Reemann P, Abram K, Vasar E, Silm H, Kõks S. Analysis of the expression profile of CRH-POMC system genes in vitiligo skin biopsies. J Dermatol Sci. 2010;60(2):125–8.PubMedCrossRef
38.
Al-Hashimi M, Scott SW, Thompson JP, Lambert DG. Opioids and immune modulation: more questions than answers. Br J Anaesth. 2013;111(1):80–8.PubMedCrossRef
39.
Hristakieva E, Lazarova R, Lazarov N, et al. Markers for vitiligo related neuropeptides in human skin nerve fibres. Acta Med Croatica. 2000;54:53–7.PubMed
40.
Miniati A, Weng Z, Zhang B, Therianou A, Vasiadi M, Nicolaidou E, Stratigos AJ, Antoniu C, Theoharides TC. Stimulated human melanocytes express and release interleukin-8, which is inhibited by luteolin: relevance to early vitiligo. Clin Exp Dermatol. 2014;39(1):54–7.PubMedCrossRef
41.
Luger TA, Schwarz T. Evidence for an epidermal cytokine network. J Invest Dermatol. 1990;95:100–4.CrossRef
42.
Schallreuter KU, Bahadoran P, Picardo M, et al. Vitiligo pathogenesis: autoimmune disease, genetic defect, excessive reactive oxygen species, calcium imbalance, or what else? Exp Dermatol. 2008;17:139–40.PubMedCrossRef
Metadaten
Titel
Vitiligo: what’s new in the psycho-neuro-endocrine-immune connection and related treatments
verfasst von
Torello Lotti, MD
Matteo Zanardelli
Angelo Massimiliano D’Erme, MD
Publikationsdatum
01.07.2014
Verlag
Springer Vienna
Erschienen in
Wiener Medizinische Wochenschrift / Ausgabe 13-14/2014
Print ISSN: 0043-5341
Elektronische ISSN: 1563-258X
DOI
https://doi.org/10.1007/s10354-014-0288-7

Weitere Artikel der Ausgabe 13-14/2014

Pathways of Tumor development and progression in Drug-induced Nonmelanoma Skin Cancer: a New Hope or the Next Great Confusion?

  • review

Pyoderma gangrenosum: pathogenetic oriented treatment approaches

  • review

Autoimmunity versus Autoinflammation - Friend or Foe?

  • main topic

Cancer, Infection and Disturbances of The Integrity of Tissue Homeostasis: The Most Significant Triggers for Molecular Mimicry and Autoimmunity in Dermatology?

  • editorial

Sarcoidosis vs. Sarcoid-like reactions: The Two Sides of the same Coin?

  • main topic

Bacterial antigens and molecular mimicry: the bridging common problematic link in the pathogenesis of sarcoidosis and sarcoid-like reactions: Isn’t it time to wake up?

  • short communication